Back
HFA Premium Access

Rationale, design and baseline characteristics of the Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) randomized controlled trial

Session: Poster Session 2 - Pharmacology and Pharmacotherapy
Topic: Cardiovascular Pharmacotherapy, Other
Speaker: Professor M. Ledwidge (Dublin, IE)
Event: Heart Failure 2019

Congress Presentation

Add to my library

Like

About the speaker

Professor Mark Ledwidge

STOP-HF Unit, Dublin (Ireland)
0 follower

12 more presentations in this session

Optimal administration timing of thiazide diuretics for sequential nephron blockade in cardiovascular patients receiving loop diuretics

Speaker: Doctor J. Fallon (Charlottesville, US)

Access
Abstract
Slides
Like
Thumbnail

Super-response to sacubitril valsartan: prevalence and clinical profile

Speaker: Mr C. Moliner-Abos (Barcelona, ES)

Access
Abstract
Like
Thumbnail

Who ARNI the best responders among patients with LVEF<35%?

Speaker: Doctor J. De Almeida (Coimbra, PT)

Access
Abstract
Like
Thumbnail

Effect of empagliflozin on hydroelectrolytic balance in patients with heart failure with reduced ejection fraction

Speaker: Doctor S. Del Prado Diaz (Madrid, ES)

Access
Abstract
Slides
Like
Thumbnail

Iron therapy in heart failure with preserved vs depressed ejection fraction

Speaker: Assistant Professor G. Alonso Salinas (Pamplona, ES)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 2 - Pharmacology and Pharmacotherapy

Speakers: Professor M. Ledwidge, Doctor J. Fallon, Mr C. Moliner-Abos, Doctor J. De Almeida, Doctor S. Del Prado Diaz...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources